MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hjh.0000000000004180

Медицинская библиотека · Journal of hypertension · 2025

Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial.

Lv Qiang, Chen Chen, Lin Ling, Zhao Xianming, Chen Junhong, Liang Zijing, Chai Yanfen, Du Bo, Sun Lei, Chen Xiaoliang, Liu Min, Zhang Xiwen, Cao Zhanwei, Zhang Hongwei, Chen Dexiong, Wang Zhifang, Zhong Yiming, Zhu Jiaying, Gao Feng, Wang Xifu, Zhang Gaoxing, Li Lipeng, Ma Jinxia, Zhao Min, Ouyang Yanhong, Guo Shubin, Wang Hengliang, Yang Ping, He Ruili, Zhao Zhichen, Sun Liming, Wu Lidong, Wu Yanqing, Liu Xianxia, Xu Tie, Li Na, Zhu Tianyi, Ma Changsheng

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеСравнительное исследованиеEquivalence TrialПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Clevidipine emulsion injection is an ultra-short-acting, intravenous calcium-channel blocker that produces a rapid and transient antihypertensive effect.

METHODS

This is a multicenter, randomized, single-blind, parallel, positive-controlled, noninferiority phase III clinical trial comparing the efficacy and safety of clevidipine and nicardipine in hypertensive emergencies. Participants were randomly assigned in a 1 : 1 ratio to the experimental group (clevidipine emulsion injection) or the positive-control group (nicardipine), and standard safety data were collected.

RESULTS

In the per-protocol set (PPS), the primary endpoint showed that 100.0% of patients in the clevidipine group achieved a 15-25% reduction in systolic blood pressure from baseline within 30 min after dosing, compared with 95.9% in the nicardipine group. The absolute difference between the two proportions was 4.1% [95% confidence interval (CI): 0.58, 7.62], with the lower bound exceeding the noninferiority margin of -10%. Secondary endpoints revealed that the median time to reach the target systolic blood pressure (defined as a 15-25% reduction from baseline) was 9.0 (9.0, 12.0) minutes for clevidipine versus 12.0 (12.0, 15.0) minutes for nicardipine, and the between-group difference was statistically significant ( P  < 0.0001). The proportions of patients who successfully transitioned to oral antihypertensive therapy within 6 h after study drug discontinuation were 96.83% for clevidipine and 95.90% for nicardipine, with no statistically significant difference ( P  = 0.7459). In the safety set (SS), the safety endpoint showed that the proportion of patients whose systolic blood pressure fell by >25% from baseline within 3 min after dosing was 0.00% for clevidipine and 0.79% for nicardipine, with no statistically significant difference ( P  = 0.4980). The overall incidence of adverse events was similar between clevidipine and nicardipine.

CONCLUSIONS

Clevidipine has similar therapeutic effects and safety compared with the nicardipine.

REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04670809.

Для цитирования: Lv Qiang, Chen Chen, Lin Ling, Zhao Xianming, Chen Junhong, Liang Zijing, Chai Yanfen, Du Bo, Sun Lei, Chen Xiaoliang, Liu Min, Zhang Xiwen, Cao Zhanwei, Zhang Hongwei, Chen Dexiong, Wang Zhifang, Zhong Yiming, Zhu Jiaying, Gao Feng, Wang Xifu, Zhang Gaoxing, Li Lipeng, Ma Jinxia, Zhao Min, Ouyang Yanhong, Guo Shubin, Wang Hengliang, Yang Ping, He Ruili, Zhao Zhichen, Sun Liming, Wu Lidong, Wu Yanqing, Liu Xianxia, Xu Tie, Li Na, Zhu Tianyi, Ma Changsheng. Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial.. Journal of hypertension. 2025. DOI: 10.1097/hjh.0000000000004180.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.